Search research articles
Contact Us
Filters
Showing results (161-170 of 193) with videos related to
Page
of 20
Sort By:
The Lancet. Oncology
|
November 26, 2015
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
Didier Meulendijks, Linda M Henricks, Gabe S Sonke, et al.
Gastroenterology
|
March 11, 2023
Lymphatic Invasion of Plakoglobin-Dependent Tumor Cell Clusters Drives Formation of Polyclonal Lung Metastases in Colon Cancer
Emre Küçükköse, Jamila Laoukili, Alexander N Gorelick, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 6, 2026
Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients
Ingrid A Franken, Steven L C Ketelaars, Carmen Rubio-Alarcón, et al.
Journal of the National Cancer Institute
|
December 5, 2021
Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology
Richard M Goldberg, Richard Adams, Marc Buyse, et al.
British Journal of Cancer
|
April 7, 2026
Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial
Maarten A Huismans, Eelke H Gort, Lisa T van der Heijden, et al.
Oncotarget
|
October 4, 2017
<i>Decoy receptor 1</i> (<i>DCR1)</i> promoter hypermethylation and response to irinotecan in metastatic colorectal cancer
Linda J W Bosch, Geert Trooskens, Petur Snaebjornsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2025
Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Lidwien P Smabers, G Emerens Wensink, Carla S Verissimo, et al.
JAMA Network Open
|
September 21, 2019
Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer
Tomasz Burzykowski, Elisabeth Coart, Everardo D Saad, et al.
Therapeutic Advances in Medical Oncology
|
July 15, 2021
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis
Jun Yin, Shaheenah Dawood, Romain Cohen, et al.
JNCI Cancer Spectrum
|
May 23, 2022
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials
Nadine J McCleary, William S Harmsen, Ellana Haakenstad, et al.
Page
of 20
Search research articles
Search
Showing results (161-170 of 193) with videos related to
Sort By:
Page
of 20
The Lancet. Oncology
|
November 26, 2015
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
Didier Meulendijks, Linda M Henricks, Gabe S Sonke, et al.
Gastroenterology
|
March 11, 2023
Lymphatic Invasion of Plakoglobin-Dependent Tumor Cell Clusters Drives Formation of Polyclonal Lung Metastases in Colon Cancer
Emre Küçükköse, Jamila Laoukili, Alexander N Gorelick, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 6, 2026
Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients
Ingrid A Franken, Steven L C Ketelaars, Carmen Rubio-Alarcón, et al.
Journal of the National Cancer Institute
|
December 5, 2021
Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology
Richard M Goldberg, Richard Adams, Marc Buyse, et al.
British Journal of Cancer
|
April 7, 2026
Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial
Maarten A Huismans, Eelke H Gort, Lisa T van der Heijden, et al.
Oncotarget
|
October 4, 2017
<i>Decoy receptor 1</i> (<i>DCR1)</i> promoter hypermethylation and response to irinotecan in metastatic colorectal cancer
Linda J W Bosch, Geert Trooskens, Petur Snaebjornsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2025
Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Lidwien P Smabers, G Emerens Wensink, Carla S Verissimo, et al.
JAMA Network Open
|
September 21, 2019
Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer
Tomasz Burzykowski, Elisabeth Coart, Everardo D Saad, et al.
Therapeutic Advances in Medical Oncology
|
July 15, 2021
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis
Jun Yin, Shaheenah Dawood, Romain Cohen, et al.
JNCI Cancer Spectrum
|
May 23, 2022
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials
Nadine J McCleary, William S Harmsen, Ellana Haakenstad, et al.
Page
of 20